Time filter

Source Type

Lopez M.A.,Institute DOncologia Radioterapica | Madrona A.P.,Hospital Universitario Virgen Of La Arrixaca | Ramos J.S.,Servicio de Oncologia Radioterapica | Bajo G.G.,Hospital General Universitario
Revista de Senologia y Patologia Mamaria | Year: 2013

Currently, conservative surgery is the standard management in breast cancer. However, in 15-35% of patients, mastectomy should be offered. Until recently, if these patients needed radiotherapy, the option of reconstruction was delayed or even rejected. Current technical advances allow both reconstruction and irradiation to be offered. This article reviews the different types of reconstructive surgery and their relationship with irradiation, including immediate heterologous reconstruction techniques, definitive prostheses, tissue expanders, delayed reconstruction with heterologous and/or autologous techniques, nipple-areola complex reconstruction, and lipofilling. We review the complications of combining radiotherapy and reconstructive surgery, and establish practical recommendations. © 2012 SESPM. Published by Elsevier España, S.L. All rights reserved.

Reig Castillejo A.,Institute DOncologia Radioterapica | Membrive Conejo I.,Institute DOncologia Radioterapica | Foro Arnalot P.,Institute DOncologia Radioterapica | Rodriguez De Dios N.,Institute DOncologia Radioterapica | Algara Lopez M.,Institute DOncologia Radioterapica
Clinical and Translational Oncology | Year: 2010

Neuroendocrine small cell carcinoma of the uterine cervix (SCC) is a rare disease that mixes clinical and biological characteristics of both cervical neoplasms and neuroendocrine small cell cancer. The prognosis is poor and the optimal treatment has not yet been clarified. Multimodality treatment, with surgery and concurrent chemoradiation has recently been shown to improve local control and survival rates. © 2010 Feseo.

Sanz J.,Institute DOncologia Radioterapica | Rodriguez N.,Institute DOncologia Radioterapica | Lio J.,Institute DOncologia Radioterapica | Foro P.,Institute DOncologia Radioterapica | And 7 more authors.
Revista de Senologia y Patologia Mamaria | Year: 2013

Introduction: We present the results of adding a hypofractionated boost after whole-breast hypofractionated radiotherapy and report patient tolerance of this procedure. Material and method: Patients were included after conservative surgery and underwent adjuvant therapy. The whole breast was treated at 2.67 Gy per fraction up to 40 Gy. The boost was performed at different dose levels (16 or 8 Gy) according to the presence of risk factors for local recurrence (tumor size, histologic grade, margin status or the presence of carcinoma in situ) or nothing in case of their absence. Results: A total of 110 patients were treated. The distribution into high-, middle- and low-risk groups was 51, 54 and 5 patients, respectively. There was no toxicity in 4.5% of the patients. Grade i or ii dermatitis was found in 38.2 and 47.3%, respectively. No differences were observed in acute dermatitis depending on boost doses. After a follow-up of 2 years, there were no chronic skin or subcutaneous changes in 79 patients (71.8%). Mild fibrosis occurred in 24 patients (21.8%) and grade ii fibrosis occurred in 7 patients. Conclusions: Hypofractionated boost seems to be well tolerated. Acute and chronic toxicities are mild. The cumulative dose does not seem to increase the incidence of fibrosis at the boost area compared with the whole breast. © 2012 SESPM. Published by Elsevier España, S.L. All rights reserved.

Discover hidden collaborations